Remove australia-news melbourne
article thumbnail

Bispecific antibody approved in Europe for DLBCL

European Pharmaceutical Review

This news follows the US Food and Drug Administration (FDA)’s approval of the anti-cancer treatment last month. The EC’s decision for Roche’s Columvi is indicated for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

FDA 72
article thumbnail

Herbal product Kamini may be causing opioid dependence in Australia, doctors warn

The Guardian - Pharmaceutical Industry

Sign up to receive an email with the top stories from Guardian Australia every morning Continue reading.

46